Skip to main content
Arthur Schwartzbard, MD, Cardiology, New York, NY

ArthurZSchwartzbardMD

Cardiology • New York, NY

Adult Congenital Heart Disease, Interventional Cardiology

Assistant Professor, Medicine, New York Univ Sch of Med

Join to view full profile

Dr. Schwartzbard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schwartzbard's full profile

Already have an account?

  • Office

    530 1st Ave
    Ste 4G
    New York, NY 10016
    Phone+1 212-263-7229

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Cardiovascular Disease, 1994 - 1997
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1990 - 1994
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 1990

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1992 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

Journal Articles

  • The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction  
    Arthur Z Schwartzbard, Jonathan D Newman, Howard S Weintraub, Jeffrey S Berger, Anish K Vani, ScienceDirect

Press Mentions

  • Ezetimibe with Statin Therapy: Biggest Bang in Higher-Risk ACS Patients
    Ezetimibe with Statin Therapy: Biggest Bang in Higher-Risk ACS PatientsAugust 22nd, 2019
  • Should We Measure Apolipoproteins to Evaluate Coronary Heart Disease Risk?
    Should We Measure Apolipoproteins to Evaluate Coronary Heart Disease Risk?January 29th, 2016
  • Advances in Cardiovascular Risk Reduction
    Advances in Cardiovascular Risk ReductionMarch 20th, 2016

Professional Memberships

Dr. Arthur Schwartzbard, Dr. Arthur Schwartzbard, MD, Dr. A Schwartzbard, Dr. Arthur Z Schwartzbard